Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GPR183 | P32249 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2380625 | 0.90 | ALDH1A1 (0.41) | HSD11B1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2380341 | 0.83 | ALDH1A1 (0.40) | HSD11B1ALDH1A1 | |
| SCHEMBL2380347 | 0.82 | CYP3A4 (0.46) | USP2CYP2D6ALOX15HSD11B1ALDH1A1 | |
| SCHEMBL2309716 | 0.81 | CYP2D6 (0.46) | USP2CYP2D6ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL2315586 | 0.81 | OPRM1 (0.45) | HSD11B1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2310708 | 0.78 | GPR183 (0.49) | USP2CYP2D6ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL2381294 | 0.78 | L3MBTL1 (0.48) | HSD11B1ALDH1A1CYP3A4CYP2C19SMN1; SMN2 | |
| SCHEMBL2379745 | 0.77 | NPC1L1 (0.46) | — | |
| SCHEMBL2311734 | 0.77 | OPRM1 (0.53) | HSD11B1SMN1; SMN2 | |
| SCHEMBL2309749 | 0.77 | OPRM1 (0.53) | HSD11B1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011115813-A1 | LACTAM ACETAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-09-22 | — | — | WO | claimed |
| US-20110230459-A1 | LACTAM ACETAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-09-22 | — | — | US | claimed |
| US-8815869-B2 | Lactam acetamides as calcium channel blockers | ABBVIE INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8044069-B2 | Compounds as calcium channel blockers | ABBOTT LABORATORIES (US) | 2011-10-25 | — | — | US | disclosed |
| WO-2011115813-A1 | LACTAM ACETAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-09-22 | — | — | WO | disclosed |
| US-20110230459-A1 | LACTAM ACETAMIDES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-09-22 | — | — | US | disclosed |
| EP-2350002-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010039947-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1S, CACNA1D | HDAC2 1635/4885HDAC1 1048/4885USP2 3774/4885 |
| US-20110230459-A1 | LACTAM ACETAMIDES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1D, CACNA1S | HDAC2 1189/4885HDAC1 305/4885USP2 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.